Method for the synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same and novel compound tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate
US-2015376126-A1 · Dec 31, 2015 · US
4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
US9675599B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9675599-B2 |
| Application number | US-201514848933-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 9, 2015 |
| Priority date | Nov 14, 2008 |
| Publication date | Jun 13, 2017 |
| Grant date | Jun 13, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to compounds of formula I: where a, R 1 , and R 3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising a compound of the formula having the chemical name 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine or a pharmaceutically acceptable salt thereof and a pharmaceuticaly acceptable carrier. 2. The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable salt is the hydrochloride salt. 3. A method of treating a pain disorder in a mammal comprising administering to the mammal the pharmaceutical composition of claim 1 . 4. The method of claim 3 wherein the pain disorder is neuropathic pain, fibromyalgia, chronic low back pain, or osteoarthritis.
Assignees
Inventors
Classifications
Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9675599B2 cover?
- The invention relates to compounds of formula I: where a, R 1 , and R 3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process …
- Who is the assignee on this patent?
- Patterson Lori Jean, Stangeland Eric L, Theravance Biopharma R&D Ip Llc
- What technology area does this patent fall under?
- Primary CPC classification C07D211/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).